caretrace.iopowered by▸healthparse
SearchCohort Builder
Tools▾
KOL FinderTerritoriesDrug Compare
AI Query
Browse▾
By stateBy specialty
Pricing
SearchCohort BuilderToolsKOL FinderTerritoriesDrug CompareAI QueryBrowseBy stateBy specialtyPricing
PROVIDER PROFILE · NPI 1801872502

Michaela TsaiMD

Hematology-OncologySeattle, WAI
CROSS-REFERENCE

Related data on other Healthparse brands

ProviderScore
OIG/SAM exclusion screening, sanctions history
© 2026 CareTrace
PricingContactPrivacyTerms
REFERRAL NETWORK

Where Michaela Tsai's patients come from & go

Directional shared-patient flow from Medicare claims — who sends patients to this provider (inbound) and where this provider's patients go next (outbound). 12 inbound referrers · 0 outbound destinations.

Receives referrals from
Inbound — who sends patients here
PhysicianPatientsVisits
BAILEY, CHERYL32191
Stuart Bloom
Medical Oncology · Minneapolis, MN
31127
John Seng
Hematology-Oncology · Minneapolis, MN
30175
Timothy Larson
Hematology-Oncology · Minneapolis, MN
29307
Robert Yost
Diagnostic Radiology · Waconia, MN
1943
KANG, EUL1937
Robin Parker
Diagnostic Radiology · Eden Prairie, MN
1838
KAYFES, MAREVE1625
SHEARER, DAMON1320
Amy Yilek
Nurse Practitioner · Minneapolis, MN
1324
John Nobrega
Diagnostic Radiology · Eden Prairie, MN
1221
Hennepin Healthcare System, Inc
Opioid Treatment Program · Minneapolis, MN
1125
Refers patients to
Outbound — where patients go next
No outbound pairs above the suppression threshold.
Source: CMS Physician Shared Patient Patterns (30-day window, Medicare FFS). Direction = a beneficiary seen by the first provider, then the second, within 30 days; a proxy for referral, not a documented referral. Pairs with fewer than 11 shared beneficiaries are suppressed.
MEDICARE UTILIZATION · PART B · 2024
Total beneficiaries
317
Unique beneficiaries
—
Total services
580
Distinct HCPCS
5
Medicare payment
$31K
Peer benchmark
Q1
Q2
Q3
Q4
Q5
Total Medicare services vs. 247 Hematology-Oncology providers in WA — below median (cohort median 770).
PRESCRIBING · PART D · 2024
Total Rx claims
664
Beneficiaries
—
Total drug cost
$612K
Distinct drugs
12
Brand share
10.4%
Top prescribed drugs
Anastrozole188 claims
Tamoxifen Citrate175 claims
Letrozole142 claims
Exemestane30 claims
Acalabrutinib Maleate25 claims
QUALITY · MIPS · 2024
Final MIPS score
79.1
Quality
81.9
Cost
40.9
Improvement activities
40.0
Promoting interop.
100.0
Payment adjustment
0.17%
Group
INDUSTRY PAYMENTS · OPEN PAYMENTS · 2024
No data available for this provider in 2024.